Scribe Therapeutics Files $107.2M IPO with Sanofi Backing

Scribe Therapeutics, a biotechnology company specializing in gene editing, has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) valued at $107.2 million. The offering is backed by French pharmaceutical company Sanofi, which has committed to purchasing shares. The company is targeting a valuation of up to $242.7 million.

IPO Details

The IPO aims to raise $107.2 million through the issuance of new shares. The number of shares and price range have not yet been disclosed, but sources indicate a target valuation of approximately $242.7 million. Sanofi, a strategic partner, will participate in the share purchase as part of the offering.

Context

Scribe Therapeutics focuses on developing gene-editing therapies for chronic diseases, with an initial emphasis on atherosclerotic cardiovascular disease (ASCVD). Phase I clinical trial data is expected to be announced in 2027. The IPO comes amid growing investor interest in gene editing, following the success of CRISPR technology.

What This Means for Investors

The IPO offers investors a chance to participate in a promising gene-editing company, but it carries high risk given the pre-revenue stage and dependence on future clinical trial results. Sanofi's backing adds credibility, but investors should monitor trial progress and regulatory approvals.